AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

⚠ The Next Switch Has to Be ReadyModerate threat

Gilead Sciences (GILD) — threat to the moat

Gilead's switching strategy needs its next HIV regimen approved years before 2036, and the weekly pill with Merck is still unapproved.

The trick of replacing your own product only works if you have the replacement. Biktarvy's earliest US generic date is 1 April 2036 under the October 2025 settlements1, and in Europe its primary patent runs to 20332. Before then Gilead needs patients on something newer.

Gilead HIV regimen hand-offs and the next candidateGenvoya$3.9bn in 2019,$1.5bn in 2025Biktarvy$14.3bn in 2025;US generics notbefore April 2036Islatravir +lenacapavironce-weekly, with Merck;positive Phase 3 in 2026Approvalnot yet grantedGilead Forms 10-K FY2021, FY2025; Q2 2026 release; Form 8-K of 6 October 2025
The next hand-off is tested but not yet approved.

The candidate is a once-weekly oral combination of islatravir and lenacapavir, developed with Merck, which produced positive Phase 3 results in the ISLEND-1 and ISLEND-2 trials3. It is not approved. And because it is a partnership, the economics will be shared in a way Biktarvy's are not.

The risk is timing. A switch made too late meets generics on the old product; one made too early sacrifices years of Biktarvy's margin. Gilead also has to persuade doctors that a weekly pill is worth disturbing a patient who is doing well on a daily one.

The prevention side has a nearer deadline. The FDA decision on oral lenacapavir as a once-weekly PrEP tablet is due on 2 February 20274, and Descovy's US patent runs to 20315. If the weekly tablet is approved on time, Gilead will have four years to move daily-pill users before Descovy's generics arrive.

The calendar is the gauge. If the weekly regimen is not approved in the United States by the end of 2028, Gilead will have less than eight years to move a $14 billion franchise.

References
  1. ReportedBiktarvy's earliest US generic date is 1 April 2036 under the October 2025 settlements, and in Europe its primary patent runs to 2033.
    Gilead Sciences Form 8-K of 6 October 2025 - settlement agreements with Lupin, Cipla and Laurus Labs; no generic entry of Biktarvy expected in the United States before 1 April 2036. — October 2025 · publ. 6 October 2025 · source ↗
  2. ReportedBiktarvy's earliest US generic date is 1 April 2036 under the October 2025 settlements, and in Europe its primary patent runs to 2033.
    Gilead Sciences Form 10-K for 2025 - patents, regulatory exclusivity, expiry dates and settlements with generic manufacturers. — FY2025 · publ. 24 February 2026 · source ↗
  3. ReportedThe candidate is a once-weekly oral combination of islatravir and lenacapavir, developed with Merck, which produced positive Phase 3 results in the ISLEND-1 and ISLEND-2 trials.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - pipeline, regulatory and business development updates. — Q2 2026 · publ. 4 August 2026 · source ↗
  4. ReportedThe FDA decision on oral lenacapavir as a once-weekly PrEP tablet is due on 2 February 2027, and Descovy's US patent runs to 2031.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - pipeline, regulatory and business development updates. — Q2 2026 · publ. 4 August 2026 · source ↗
  5. ReportedThe FDA decision on oral lenacapavir as a once-weekly PrEP tablet is due on 2 February 2027, and Descovy's US patent runs to 2031.
    Gilead Sciences Form 10-K for 2025 - Item 1A risk factors and pricing regulation: the IRA, Medicare negotiation, Medicaid, the ACA and tariffs. — FY2025 · publ. 24 February 2026 · source ↗
Sources
Generated October 4, 2026